Table 4.
Covariate | Level | Median OS Time (mo) | Median PFS Time (mo) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total | Failed | Censored | Median (95% CI) | P-value | Total | Failed | Censored | Median (95% CI) | P-value | ||
All patients | 74 | 60 | 14 | 8.11 (6.18, 9.63) | 74 | 70 | 4 | 3.71 (2.79, 4.21) | |||
Treatment | Bevacizumab | 30 | 23 | 7 | 9.26 (5.88, 11.37) | 0.6398 | 30 | 29 | 1 | 3.94 (1.94, 5.68) | 0.9401 |
Bevacizumab + vorinostat | 44 | 37 | 7 | 7.79 (5.06, 9.63) | 44 | 41 | 3 | 3.68 (2.33, 3.94) |